24日下午,医药股康哲药业(00867)在港股盘中大涨6.38%,一度触及8.24港元/股的高点,成交活跃。业内分析人士指出,康哲药业作为专注于创新药物研发的药企,其股价大涨或主要受益于医药行业整体向好的前景。
康哲药业是一家开放式平台型企业,致力于提供有竞争力的医药产品并满足未满足医疗需求。公司专注于研发全球首创和同类最优的创新产品,在心脑血管、消化等领域的创新药物管线丰富,并将皮肤、眼科业务独立运营。近期财报显示,公司营收和净利润保持稳健增长,市盈率水平合理。
与此同时,医药行业整体表现也相当活跃。数据显示,24日港股医药生物行业整体上涨0.06%,其中石药集团、励晶太平洋等相关个股涨幅较大。分析师认为,随着人口老龄化加剧和新冠疫情影响减退,各国对医疗卫生的重视程度加大,增加了对创新药物的需求,这是支撑医药行业向好的重要因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.